Fast track cell, gene & car-t commercialization from concept to robust patient-centric delivery.

Cell and Gene Therapy Report 2020: Viral and Non-viral Vectors

Share this article

Viral and non-viral vectors are crucial gene delivery vehicles for cell and gene therapies, yet they are difficult to manufacture to a scale that meets the growing demand. Across vector characterization, raw materials and supply chain, there are many limitations and obstacles to consider.

In April 2020, we conducted a survey of cell and gene therapy professionals all over the world, to find out what difficulties they were experiencing, and which areas were in the greatest need of innovation.

The final report provides insight into the biggest opportunities and challenges surrounding viral and non-viral vector manufacturing which are ready to be addressed.

Key Insights

  • 59% of the participants are working with viral methods when considering viral gene therapy delivery.
  • 61% of the respondents see encountering stability issues as the main hurdle when cryopreserving their vectors.
  • Viral vectors used in production and plasmids were voted to be the most limiting when considering raw and starting materials used in viral vector manufacturing.

Click the image below to begin exploring the ebook.
Viral and Non-Viral Vectors Survey Report 2020

Share this article

Subscribe to our Cell & Gene Therapy newsletter

Upcoming event

Cell & Gene Therapy Manufacturing & Commercialization Asia

05 - 08 Apr 2021
The ONLY Cell and Gene Therapy event in Asia to help you fast track manufacturing & commercialization across borders
Go to site